Desmosterol Test

Your standard lipid panel tells you how much cholesterol is floating around in your blood. What it cannot tell you is where that cholesterol came from. Your body has two main sources: it absorbs cholesterol from the food you eat, and it builds cholesterol from scratch inside your cells (mostly in your liver). Whether your cholesterol is high because you absorb too much or because you produce too much changes what you should do about it. Desmosterol (cholesta-5,24-dien-3-beta-ol) is one of the few blood tests that can help answer that question.

Desmosterol is the very last molecule your liver makes before it becomes cholesterol. An enzyme called DHCR24 (24-dehydrocholesterol reductase) performs the final conversion. When your body ramps up cholesterol production, more desmosterol enters your bloodstream. When production slows, desmosterol falls. This makes it a direct window into how hard your cholesterol assembly line is running, and it is especially useful in the context of fatty liver disease and inherited lipid conditions.

How Desmosterol Fits Into Cholesterol Production

Your cells build cholesterol through a long chain of chemical steps. The late stages of this process split into two parallel routes. One route, called the Bloch pathway, ends with desmosterol as the second-to-last product. The other route, called the Kandutsch-Russell pathway, uses a different intermediate called lathosterol. Both routes converge on cholesterol as the final product. Desmosterol reflects the output of the Bloch pathway specifically.

A key advantage of desmosterol over lathosterol as a synthesis marker is stability. Research in healthy men found that desmosterol lacks the time-of-day fluctuations seen with lathosterol, making it a more consistent snapshot of your production rate regardless of when you draw blood. This does not mean a single reading is definitive, but it does mean you are less likely to get a misleading result simply because of when you happened to visit the lab.

Desmosterol is often ordered alongside absorption markers like campesterol and beta-sitosterol (plant sterols that enter your blood from your gut). Together, these sterols create a "cholesterol balance" picture: is your body tilted toward overproduction, overabsorption, or both? A validated population study of randomly selected men confirmed that serum desmosterol levels track closely with directly measured whole-body cholesterol synthesis and inversely with cholesterol absorption.

Fatty Liver Disease

The strongest clinical evidence for desmosterol comes from fatty liver research. In a study of 110 obese adults undergoing weight-loss surgery (bariatric surgery) who had liver biopsies, those with biopsy-confirmed NASH (nonalcoholic steatohepatitis, a form of fatty liver disease involving both fat buildup and inflammation) had significantly higher serum desmosterol and higher desmosterol-to-cholesterol ratios than obese individuals with normal livers or simple fat accumulation without inflammation.

What made desmosterol stand out was how closely the blood level matched what was happening inside the liver. The correlation between serum desmosterol and liver tissue desmosterol was strong (a statistical correlation of about 0.67, where 1.0 would be a perfect match). Serum desmosterol also correlated with the degree of liver fat, the severity of liver inflammation, and the amount of cholesterol trapped inside liver tissue. These correlations were stronger than those seen with standard total or LDL cholesterol.

In a separate population cohort of 717 men from the same research group, desmosterol and its ratio to cholesterol were associated with ALT (alanine aminotransferase, a standard liver enzyme test) more strongly than routine lipid measurements. Higher desmosterol tracked with obesity, central body fat, and insulin resistance.

More recent research in people with metabolic dysfunction-associated steatotic liver disease (MASLD, the updated term for what was previously called NAFLD) confirmed that desmosterol correlates positively with several non-invasive indicators of liver fat, including the fatty liver index and the triglyceride-glucose index. This pattern supports the idea that fatty liver disease is driven in part by the liver overproducing cholesterol, and that desmosterol captures this process in a way standard tests do not.

Inherited Lipid Disorders

People with familial combined hyperlipidemia (FCH, an inherited condition causing high cholesterol and triglycerides that runs in families) show about 31% higher desmosterol levels compared to people without FCH. In that same research, desmosterol correlated positively with body mass index, blood sugar, insulin, ApoB (apolipoprotein B, the protein on LDL particles), triglycerides, and LDL cholesterol.

An interesting finding was that postmenopausal women with FCH had notably higher desmosterol than premenopausal women with the same condition, suggesting that estrogen status may influence the enzyme (DHCR24) that converts desmosterol into cholesterol. If you have a family history of combined high cholesterol and triglycerides, desmosterol can help clarify whether overproduction is a major driver of your lipid pattern.

Understanding Your Results

This is a Tier 3, research-grade biomarker. No medical guidelines have established standardized clinical cutpoints for serum desmosterol. Different labs may use different methods (typically specialized laboratory techniques such as gas chromatography-mass spectrometry), and results are reported either as an absolute concentration in mg/L or as a ratio to total cholesterol. The ratio form adjusts for your overall cholesterol level and is commonly used in research, but the absolute concentration (which is what this test reports in mg/L) is a direct readout.

Because no universal "normal" or "optimal" ranges exist, the most meaningful way to interpret your result is in context: alongside companion sterols (lathosterol, campesterol, beta-sitosterol), your standard lipid panel, and liver function tests. A high desmosterol relative to absorption markers suggests your body favors making cholesterol over absorbing it. A low desmosterol with high plant sterols suggests the opposite.

The clinical maturity of this test means you should not make treatment decisions based on a single desmosterol reading alone. It is best used as one piece of a larger cholesterol metabolism puzzle, especially if you are trying to understand why your cholesterol is elevated or whether a fatty liver diagnosis reflects disturbed cholesterol production.

When Results Can Be Misleading

Certain medications can shift desmosterol without causing the metabolic conditions the test is meant to detect. The antidepressant trazodone has been shown to decrease serum desmosterol while markedly increasing a different cholesterol precursor (7-dehydrocholesterol) in human blood. If you are taking trazodone, your desmosterol reading may appear artificially low, potentially masking elevated cholesterol synthesis. Other psychotropic drugs, including some antipsychotics like aripiprazole and haloperidol, may also alter sterol precursor profiles, though desmosterol-specific data for these drugs is limited.

If you are taking any cholesterol-lowering medication, your results will reflect the drug's effect on the synthesis pathway. Statins reduce desmosterol by slowing the entire cholesterol production chain upstream. Ezetimibe, which blocks cholesterol absorption in the gut, triggers the body to compensate by ramping up production, which raises desmosterol. If you are on both, the net effect depends on which mechanism dominates. These are real biological shifts, not artifacts, but you need to interpret them in the context of your medication.

Unlike lathosterol, desmosterol does not appear to have meaningful time-of-day fluctuations, so the timing of your blood draw is less of a concern. No data exists on whether acute illness, surgery, or recent intense exercise meaningfully shifts desmosterol in the short term. The formal within-person biological variation (how much your level bounces around day to day) has not been published for desmosterol, which is another reason to rely on trends rather than single values.

Tracking Your Trend

Because desmosterol lacks standardized clinical thresholds, tracking your personal trend over time is more valuable than any single reading. A baseline measurement establishes your starting point. If you make changes to your diet, exercise habits, or medication, retesting in 3 to 6 months lets you see whether those changes shifted your cholesterol production rate. After that, annual monitoring is reasonable if you are using this test as part of a broader metabolic assessment.

When retesting, use the same lab and the same assay method each time. Sterol measurements can vary between labs and techniques, so comparing results across different labs introduces noise that can obscure real changes. Your own trajectory within one lab is the most reliable signal. As the science around this marker matures and population-based reference ranges are established, having your own longitudinal data will give you a head start on interpreting where you fall.

What to Do With Your Results

If your desmosterol is elevated relative to absorption markers, the pattern suggests your body is a cholesterol overproducer. This is useful information because it may influence which lipid-lowering strategy works best for you. Statins, which directly block the production pathway, tend to be more effective in overproducers. Ezetimibe, which blocks absorption, tends to work better in overabsorbers. A sterols panel that includes both synthesis and absorption markers helps make this distinction.

If your desmosterol is high alongside elevated liver enzymes (especially ALT), that combination raises the suspicion of disturbed liver cholesterol metabolism and possible fatty liver disease. The next step would be liver imaging (ultrasound or a FibroScan) and a broader metabolic workup including fasting insulin, HbA1c, and a full lipid panel. A hepatologist or lipidologist can help interpret this pattern.

If your result is unremarkable and your standard lipid panel and liver enzymes are normal, that is reassuring. It suggests your cholesterol production rate is not a hidden driver of risk. You can retest annually or when your clinical picture changes.